High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent manner
Tang, F.; Lan, T.; Liu, Z.; Wang, Z.-F.; Li, Z.-Q.
Show abstract
ObjectiveHigh tumor mutational burden (TMB) is a promising biomarker for patients with immunotherapy in certain types of solid tumors. This article focuses on exploring possible universally optimal cutoffs of TMB for predicting immune checkpoint inhibitors (ICIs) response and prognosis for eight types of cancers. MethodsThe present study collected eight types of tumors including 2767 patients receiving immune checkpoint inhibitors (ICIs) treatment and 14862 patients without ICI treatment. We tried to explore optimal cutoffs of TMB in each type of tumor via selecting several possible cutoffs of TMB including 10mut/Mb, top 10%, 20%, and 30% of TMB within each histology. ResultsWe found that there was a significant difference in TMB values between ICI-treated and non-ICI-treated groups. The cutoff of TMB appropriate for predicting response rates, progression rates, and survival rates was varied in ICI therapy patients. Moreover, the optimal cutoff of TMB for predicting progression-free survival and overall survival in different types of the tumor was also quietly different. ConclusionOur current study suggested that TMB predicts prognosis and responses to ICI treatment in a cancer-dependent manner.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Patient stratification of clear cell renal cell carcinoma using the global transcription factor activity landscape derived from RNA-seq data 95%
- Establishment of a prognosis prediction model based on pyroptosis-related signatures associated with the immune microenvironment and molecular heterogeneity in clear cell renal carcinoma 94%
- BNIP3 upregulation characterizes cancer cell subpopulation with increased fitness and proliferation 94%
Similar papers in this journal
- Hormone Receptor-status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape 94%
- COL7A1 expression improves prognosis prediction for patients with clear cell renal cell carcinoma atop of stage 94%
- A novel molecular analysis approach in colorectal cancer suggests new treatment opportunities 94%
Similar papers in this journal
- Enhancing Chemotherapy Response Prediction via Matched Colorectal Tumor-Organoid Gene Expression Analysis and Network-Based Biomarker Selection 96%
- ORMDL1 is upregulated and associated with favorable outcome in colorectal cancer 94%
- Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum 93%
Similar papers in this journal
- Bioinformatics analysis of immune-related prognostic genes and immunotherapy in renal clear cell carcinoma 96%
- Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: a retrospective cohort study 95%
- Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.